Form 4 for AORT ARTIVION, INC.
Accepted 2023-02-16 00:00:00 ET · period of report 2023-02-14 · accession 0000784199-23-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-16 | 2023-02-14 | AORT | LEE DAVID ASHLEY | COO, CFO, Executive VP | S - Sale+OE | $13.22 | -31.9K | 335.6K | -9% | -$421.7K |
| D | 2023-02-16 | 2023-02-14 | AORT | LEE DAVID ASHLEY | COO, CFO, Executive VP | M - OptEx | $10.24 | +36.8K | 367.5K | +11% | +$377.1K |
| D | 2023-02-16 | 2023-02-14 | AORT | LEE DAVID ASHLEY | COO, CFO, Executive VP | M - OptEx | $10.24 | -36.8K | 0 | -100% | -$377.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-14 | S | D | 31,900 | $13.22 | 335,563 | D | — | — | (F1) The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on November 14, 2022 (F2) Reflects the price of $ 13.224856 the shares were sold. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at this price |
| 2 | Common | Common Stock | 2023-02-14 | M | A | 36,822 | $10.24 | 367,463 | D | — | — | (F1) The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on November 14, 2022 |
| 3 | Derivative | Stock Options (Right to buy) | 2023-02-14 | M | D | 36,822 | $10.24 | 0 | D | $10.24 · 2017-02-19 to 2023-02-19 | 36,822 Common Stock | (F3) Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 2/19/2017. |